KLOW Blend Regulatory Audit in Brookfield: Four Ingredients, Four Separate Evidence Records
A consultation-checklist approach to GHK-Cu, KPV, BPC-157, and TB-500 without blend-level claims.
KLOW combines four substances with different FDA records. This Brookfield checklist audits GHK-Cu, KPV, BPC-157, and TB-500 separately and does not claim that the blend has been validated, is available, or produces a clinical result.
- Christopher Patino, APRN, Adult-Gerontology
- Dr. Yessenia Quirola, DNP, APRN, FNP-BC, NP-CThe “Dr.” title reflects Dr. Quirola's Doctor of Nursing Practice (DNP) degree — not an MD or DO.
- FDA has not validated KLOW as a four-ingredient combination.
- GHK-Cu is under evaluation for non-injectable routes; that status is not approval and excludes injectable routes.
- FDA separately proposed non-inclusion of KPV-, BPC-157-, and TB-500-related substances on the 503A Bulks List.
- Component-level discussion cannot establish blend-level safety, effectiveness, or expected results.
Audit the ingredients one by one
KLOW is a named combination of GHK-Cu, KPV, BPC-157, and TB-500. FDA has not validated this four-ingredient blend as a combined product. Evidence or regulatory discussion about one component cannot be transferred to the blend or to another component.
GHK-Cu: under evaluation is not approval
FDA’s 503A categories update lists GHK-Cu, except injectable routes, in Category 1—bulk drug substances under evaluation. The document says FDA intends to consult PCAC regarding potential inclusion on the 503A Bulks List. Category 1 is not FDA approval, authorization to market, or a final decision. The route limitation is material: the listed status expressly excludes injectable routes.
KPV: limited characterization and no human clinical evidence identified
At the July 2026 meeting, FDA evaluated KPV free base and acetate for wound-related and inflammatory nominated uses. The KPV briefing document describes both substances as not well characterized, identifies missing impurity, aggregate, and microbial information, and states that potential safety risks in humans are unknown. FDA reported finding no clinical studies in humans for the nominated uses and proposed that the substances not be included on the 503A Bulks List.
BPC-157: a separate proposal based on a separate record
FDA evaluated BPC-157 free base and acetate for ulcerative colitis. Its BPC-157 briefing document describes characterization gaps, insufficient clinical safety information, immunogenicity questions, and insufficient evidence for the evaluated use. FDA proposed non-inclusion on the 503A Bulks List. That proposal concerns BPC-157-related bulk substances; it does not validate KLOW as a combination.
TB-500: unknown human safety and evidence gaps
FDA evaluated TB-500 free base and acetate for a wound-related nominated use. The TB-500 briefing document identifies missing information about impurities, aggregates, bioburden, and endotoxins. FDA reported that potential human safety risks are unknown and that it found no clinical studies or human exposure data supporting the evaluated use. FDA proposed non-inclusion on the 503A Bulks List.
A Brookfield consultation-checklist lens
VidaVital’s verified Brookfield record places the clinic on West North Avenue, near I-94 and Bluemound Road, serving southeastern Wisconsin. For any named combination discussed in educational material, a responsible checklist separates four questions: What exactly is each ingredient? What route is being discussed? What does FDA’s current record say for that ingredient? Has the combination itself been studied? For KLOW, this page makes no blend-level effectiveness, safety, regenerative, or guaranteed-result claim and does not state that the blend is available.
The FDA PCAC meeting page also makes the process boundary clear: advisory committee recommendations are non-binding. FDA proposals and committee consideration must not be rewritten as approval.
Continue with verified VidaVital resources
Has FDA evaluated KLOW as a four-ingredient blend?
No FDA source cited here validates the four-ingredient combination as a product.
Does GHK-Cu Category 1 status mean FDA approval?
No. Category 1 means under evaluation. FDA’s 2026 update excludes injectable routes and anticipates future PCAC consultation.
What did FDA propose for KPV, BPC-157, and TB-500?
FDA separately proposed that the related free-base and acetate substances not be included on the 503A Bulks List.
Does this Brookfield page promise a result or state that KLOW is available?
No. It is an ingredient-by-ingredient regulatory checklist with no blend-validation, availability, or outcome claim.
FDA regulatory and advisory materials are summarized for patient education. Clinical review was completed on September 14, 2026.
- July 23–24, 2026 Pharmacy Compounding Advisory Committee Meeting
- FDA Presentations for the July 23, 2026 PCAC Meeting
- FDA 503A Bulk Drug Substance Categories Update: GHK-Cu
- FDA Briefing Document: KPV-Related Bulk Drug Substances
- FDA Briefing Document: BPC-157-Related Bulk Drug Substances
- FDA Briefing Document: TB-500-Related Bulk Drug Substances